EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Immunotherapy resistance and strategies in malignant pleural mesothelioma

Wanyi Xia, Yulong Zhang, Juanzhi Zhao, Xiaoli Tan, Shaolong Ju, Wei Zou, Chaoqun Chen, Chunwei Li, Yanghua Xu, Yingming Peng, Shengqiao Li

Cancer Drug Resistance · 26.03.2026

DOI: 10.20517/cdr.2025.215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 26.03.2026. Verfasst von Wanyi Xia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China. Die Arbeit nennt 206 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy, resulting in persistently poor survival outcomes. The advent of immune checkpoint inhibitors (ICIs) has fundamentally reshaped the therapeutic landscape of MPM. Notably, dual programmed cell death protein 1 (PD-1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade has demonstrated superior efficacy over monotherapy in multiple phase I/II trials and has been established as a novel first-line standard of care. Nevertheless, the high incidence of resistance continues to pose a major clinical challenge. This therapeutic bottleneck is largely attributed to the unique biology of MPM, including a profoundly immunosuppressive tumor microenvironment, aberrantly activated signaling pathways, and complex metabolic reprogramming, which together form a multilayered defense network against immune attack. In response to this intricate resistance architecture, recent research efforts have increasingly focused on the development of precision combination strategies. By rationally integrating ICIs with anti-angiogenic agents, chemotherapy, metabolic modulators, and next-generation cellular immunotherapies [e.g., chimeric antigen receptor T cells (CAR-T), chimeric antigen receptor-natural killer (CAR-NK)], these approaches aim to dismantle immune evasion barriers and reinvigorate antitumor immunity. Concurrently, the discovery of novel biomarkers and their integration with multi-omics data are enabling more precise patient stratification, signaling the advent of an era of personalized immunotherapy for MPM. This review provides a systematic synthesis of the latest clinical advances and fundamental breakthroughs in MPM immunotherapy, with a particular focus on dissecting the multifactorial mechanisms underlying therapeutic resistance. Its core contribution lies in constructing a forward-looking framework for next-generation treatment strategies. It critically evaluates the translational potential of emerging approaches, including arginine deprivation therapy for argininosuccinate synthase 1 (ASS1)-deficient tumors, CAR-T cells, T-cell receptor fusion constructs, and oncolytic virotherapy. By integrating these innovative modalities with biomarker-guided patient selection, this review delineates a roadmap for transitioning MPM management from empirical therapy toward precision immuno-oncology, with the ultimate goal of achieving durable disease control in this challenging malignancy.

Schlagwörter

Stichwörter der Autor:innen

Malignant pleural mesotheliomaimmunotherapyresistance to immune checkpoint inhibitorstumor microenvironment

Autor:innen und Institutionen

  • Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China.
  • Clinical Pharmaceutics Room, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China.
  • Experimental Research Department, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China.
  • Center for Infection and Immunity Research, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China.
  • Clinical Lab, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, Guangdong, China.

Zitieren

APA

Xia, W., Zhang, Y., Zhao, J., Tan, X., Ju, S., Zou, W., Chen, C., Li, C., Xu, Y., Peng, Y., & Li, S. (2026). Immunotherapy resistance and strategies in malignant pleural mesothelioma. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.215

Vancouver

Xia W, Zhang Y, Zhao J, Tan X, Ju S, Zou W, et al. Immunotherapy resistance and strategies in malignant pleural mesothelioma. Cancer Drug Resistance. 2026. doi:10.20517/cdr.2025.215

BibTeX
@article{Xia2026,
  author = {Xia, Wanyi and Zhang, Yulong and Zhao, Juanzhi and Tan, Xiaoli and Ju, Shaolong and Zou, Wei and Chen, Chaoqun and Li, Chunwei and Xu, Yanghua and Peng, Yingming and Li, Shengqiao},
  title = {Immunotherapy resistance and strategies in malignant pleural mesothelioma},
  journal = {Cancer Drug Resistance},
  year = {2026},
  doi = {10.20517/cdr.2025.215}
}
Kostenlos starten →